Vical (VICL) Shares Down 1%

Share on StockTwits

Vical Incorporated (NASDAQ:VICL) traded down 1% during mid-day trading on Friday . The stock traded as low as $0.90 and last traded at $0.99. 12,057 shares traded hands during trading, a decline of 83% from the average session volume of 72,088 shares. The stock had previously closed at $1.00.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Vical from a “hold” rating to a “strong-buy” rating and set a $1.50 price objective for the company in a research report on Friday, November 2nd. HC Wainwright set a $4.00 price objective on shares of Vical and gave the stock a “buy” rating in a research report on Tuesday, October 30th.

The stock has a market cap of $24.33 million, a price-to-earnings ratio of -0.99 and a beta of 0.65.

Vical (NASDAQ:VICL) last released its earnings results on Monday, October 29th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.08. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.18 million. Vical had a negative net margin of 300.44% and a negative return on equity of 31.61%. Equities research analysts predict that Vical Incorporated will post -0.85 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in Vical by 47.5% in the third quarter. JPMorgan Chase & Co. now owns 138,960 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 44,723 shares in the last quarter. BlackRock Inc. grew its position in Vical by 20.0% in the second quarter. BlackRock Inc. now owns 394,320 shares of the biotechnology company’s stock valued at $453,000 after purchasing an additional 65,732 shares in the last quarter. Renaissance Technologies LLC grew its position in Vical by 10.1% in the third quarter. Renaissance Technologies LLC now owns 966,549 shares of the biotechnology company’s stock valued at $1,324,000 after purchasing an additional 88,820 shares in the last quarter. Finally, Sio Capital Management LLC bought a new position in Vical in the third quarter valued at $1,699,000. 47.27% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first reported by Macon Daily and is owned by of Macon Daily. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://macondaily.com/2019/01/11/vical-vicl-shares-down-1.html.

About Vical (NASDAQ:VICL)

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.

Recommended Story: What strategies should day traders use to execute a trade?

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply